📗 Cite This Artifact
LAG3 Protein (CD223)
LAG3 Protein (CD223)
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">LAG3 Protein (CD223)</th>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Blocking antibodies</td>
<td>Prevent fibril binding/uptake</td>
</tr>
<tr>
<td class="label">Soluble LAG3</td>
<td>Decoy receptor for fibrils</td>
</tr>
<tr>
<td class="label">Small molecule inhibitors</td>
<td>Block LAG3-fibril interaction</td>
</tr>
<tr>
<td class="label">Interacting Partner</td>
<td>Type</td>
</tr>
<tr>
<td class="label">MHC Class II</td>
<td>Physiological</td>
</tr>
<tr>
<td class="label">Alpha-synuclein fibrils</td>
<td>Pathological</td>
</tr>
<tr>
<td class="label">Tau fibrils</td>
<td>Pathological</td>
</tr>
<tr>
<td class="label">Fibrinogen-like protein 1</td>
<td>Physiological</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">6 edges</a></td>
</tr>
</table>
LAG3 Protein (CD223)
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">LAG3 Protein (CD223)</th>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Blocking antibodies</td>
<td>Prevent fibril binding/uptake</td>
</tr>
<tr>
<td class="label">Soluble LAG3</td>
<td>Decoy receptor for fibrils</td>
</tr>
<tr>
<td class="label">Small molecule inhibitors</td>
<td>Block LAG3-fibril interaction</td>
</tr>
<tr>
<td class="label">Interacting Partner</td>
<td>Type</td>
</tr>
<tr>
<td class="label">MHC Class II</td>
<td>Physiological</td>
</tr>
<tr>
<td class="label">Alpha-synuclein fibrils</td>
<td>Pathological</td>
</tr>
<tr>
<td class="label">Tau fibrils</td>
<td>Pathological</td>
</tr>
<tr>
<td class="label">Fibrinogen-like protein 1</td>
<td>Physiological</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">6 edges</a></td>
</tr>
</table>
<div style="float: right; width: 280px; background: #f8f9fa; border: 1px solid #ddd; padding: 12px; margin: 0 0 1em 1em; font-size: 0.9em;">
<h4 style="margin-top: 0; color: #3366cc;">LAG3 (CD223)</h4>
<table style="width: 100%; border-collapse: collapse;">
<tr><td style="padding: 4px; border-bottom: 1px solid #eee;"><strong>UniProt ID</strong></td><td style="padding: 4px; border-bottom: 1px solid #eee;">[P18627](https://www.uniprot.org/uniprotkb/P18627)</td></tr>
<tr><td style="padding: 4px; border-bottom: 1px solid #eee;"><strong>Gene</strong></td><td style="padding: 4px; border-bottom: 1px solid #eee;">[LAG3](/genes/lag3)</td></tr>
<tr><td style="padding: 4px; border-bottom: 1px solid #eee;"><strong>MW</strong></td><td style="padding: 4px; border-bottom: 1px solid #eee;">~57 kDa</td></tr>
<tr><td style="padding: 4px; border-bottom: 1px solid #eee;"><strong>Location</strong></td><td style="padding: 4px; border-bottom: 1px solid #eee;">Cell membrane, immune cells</td></tr>
<tr><td style="padding: 4px; border-bottom: 1px solid #eee;"><strong>PDB</strong></td><td style="padding: 4px; border-bottom: 1px solid #eee;">[1Z2M](https://www.rcsb.org/structure/1Z2M)</td></tr>
</table>
</div>
Overview
LAG3 Protein is a protein that lag3 is primarily expressed on activated t cells, regulatory t cells (tregs), natural killer cells, and to a lesser extent on b cells and dendritic cells. its canonical functions include:[@woo2012]. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target.
LAG3 Protein (CD223)
LAG3 (Lymphocyte Activation Gene 3, also known as CD223) is a cell surface receptor protein belonging to the immunoglobulin superfamily that has emerged as a critical mediator of pathological protein spreading in neurodegenerative diseases, particularly [Parkinson's disease](/diseases/parkinsons-disease).[@mao2016]
Structure and Domain Architecture
LAG3 is a type I transmembrane glycoprotein composed of:
- Extracellular domain: Contains four immunoglobulin-like (Ig-like) domains (D1-D4) with structural homology to [CD4](/proteins/cd4)
- Transmembrane domain: Anchors the protein to the plasma membrane
- Cytoplasmic tail: Contains a unique "KIEELE" motif essential for inhibitory signaling[@workman2014]
The D1 domain contains a "loop" structure formed by an extra disulfide bond that is not present in CD4, giving LAG3 its distinctive binding properties. The protein forms homodimers on the cell surface, which is important for its signaling function.
Normal Function
LAG3 is primarily expressed on activated T cells, regulatory T cells (Tregs), natural killer cells, and to a lesser extent on B cells and dendritic cells. Its canonical functions include:[@woo2012]
Role in Neurodegeneration
Alpha-Synuclein Spreading in Parkinson's Disease
The discovery that LAG3 serves as a receptor for pathological [alpha-synuclein](/proteins/alpha-synuclein) fibrils represents a major breakthrough in understanding disease propagation in [Parkinson's disease](/diseases/parkinsons-disease):[@mao2016]
The interaction occurs primarily through the D1 domain of LAG3. Antibodies blocking this interaction prevent fibril uptake and seeding in experimental models.
Tau Pathology
LAG3 has also been implicated in [tau](/proteins/tau) spreading:[@holmes2013]
- LAG3 binds to [tau](/proteins/tau) fibrils with lower affinity than alpha-synuclein
- May contribute to tau propagation in certain contexts
- Interaction less well-characterized than alpha-synuclein binding
Neuroinflammation
Beyond protein spreading, LAG3 contributes to neurodegeneration through immune modulation:[@mckinney2021]
- Microglial activation: LAG3 expression on microglia influences inflammatory responses
- T cell infiltration: LAG3 regulates T cell entry into the CNS during neuroinflammation
- Immune checkpoint: Altered LAG3 signaling in neurodegenerative conditions
Therapeutic Targeting
LAG3 represents a promising therapeutic target for neurodegenerative diseases:
Anti-LAG3 Strategies for Neurodegeneration
Cancer Immunotherapy Context
LAG3-targeting antibodies (relatlimab) are FDA-approved for cancer immunotherapy, providing clinical validation of the target. However, these agents are designed to activate LAG3's immune checkpoint function, whereas neurodegeneration therapy would require blocking the receptor's binding to pathological proteins.[@tawbi2022]
Protein Interactions
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
See Also
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- Immune Checkpoint Proteins
- Protein Spreading in Neurodegeneration
References
Pathway Diagram
The following diagram shows the key molecular relationships involving LAG3 Protein (CD223) discovered through SciDEX knowledge graph analysis:
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | proteins-lag3 |
| kg_node_id | LAG3 |
| entity_type | protein |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-735d89f4d211 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-lag3'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-proteins-lag3?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[LAG3 Protein (CD223)](http://scidex.ai/artifact/wiki-proteins-lag3)
http://scidex.ai/artifact/wiki-proteins-lag3